Stay Updated

Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.

No spam, ever. Unsubscribe anytime.

David Hough

From Janssen Research and Development, Titusville, N.J., and San Diego; Janssen Scientific Affairs, Titusville, N.J.; and the Department of Psychiatry, Yale School of Medicine, New Haven, Conn.

Studies (4)

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).

28. Jan. 2022RCTCo-Author

Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.

21. Mai 2021ObservationalCo-Author

Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).

14. Sept. 2020RCTCo-Author

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.

8. Juli 2019RCTCo-Author

Overview

Publications: 4
Lead Author: 0
Co-Author: 4

Study Types

RCT3

Observational1

Links

—

X LinkedIn Email